Driehaus Capital Management LLC bought a new stake in Fate Therapeutics, Inc. (NASDAQ:FATE) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm bought 31,790 shares of the biopharmaceutical company’s stock, valued at approximately $145,000. Driehaus Capital Management LLC owned about 0.08% of Fate Therapeutics as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also modified their holdings of FATE. Creative Planning raised its position in shares of Fate Therapeutics by 35.3% in the first quarter. Creative Planning now owns 23,000 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 6,000 shares during the period. KCG Holdings Inc. raised its position in shares of Fate Therapeutics by 7.8% in the first quarter. KCG Holdings Inc. now owns 24,480 shares of the biopharmaceutical company’s stock worth $111,000 after buying an additional 1,764 shares during the period. Hillsdale Investment Management Inc. acquired a new position in shares of Fate Therapeutics during the first quarter worth approximately $160,000. Segantii Capital Management Ltd acquired a new position in shares of Fate Therapeutics during the first quarter worth approximately $182,000. Finally, TFS Capital LLC acquired a new position in shares of Fate Therapeutics during the first quarter worth approximately $248,000. 60.47% of the stock is currently owned by institutional investors.
Fate Therapeutics, Inc. (NASDAQ:FATE) opened at 2.83 on Thursday. The company has a 50 day moving average price of $3.15 and a 200-day moving average price of $3.70. Fate Therapeutics, Inc. has a 52-week low of $1.80 and a 52-week high of $5.68. The firm’s market cap is $117.16 million.
Fate Therapeutics (NASDAQ:FATE) last announced its quarterly earnings results on Monday, May 15th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by $0.03. The company had revenue of $1.03 million during the quarter, compared to the consensus estimate of $1.04 million. Fate Therapeutics had a negative net margin of 857.34% and a negative return on equity of 75.93%. Equities research analysts anticipate that Fate Therapeutics, Inc. will post ($1.00) EPS for the current year.
WARNING: “Driehaus Capital Management LLC Invests $145,000 in Fate Therapeutics, Inc. (FATE)” was originally reported by BBNS and is the property of of BBNS. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://baseballnewssource.com/markets/driehaus-capital-management-llc-invests-145000-in-fate-therapeutics-inc-fate-updated-updated/1161325.html.
Separately, Wedbush reaffirmed an “outperform” rating and set a $7.00 target price on shares of Fate Therapeutics in a report on Tuesday, May 16th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Fate Therapeutics presently has an average rating of “Buy” and an average target price of $6.25.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc. and related companies with our FREE daily email newsletter.